Physician profile
Manoj Das
NPI 1174873988
$1,910.34
in general payments reported to CMS, 2019-2025
18 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.37 · 2023: $3.11 · 2024: $1,027 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881 · Education: $4.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.75 |
| Education | $4.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $467.42 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $254.06 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $182.46 | 2024-2025 | Velphoro, Nxstage System One |
| Vifor Pharma, INC. | $132.18 | 2024-2025 | Veltassa |
| Amgen INC. | $116.96 | 2022-2025 | Tavneos |
| Lilly USA, LLC | $112.45 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $110.09 | 2024-2025 | Lokelma |
| Calliditas Therapeutics US INC. | $100.34 | 2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $66.88 | 2024-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $64.52 | 2024-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.15 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $51.14 | 2023-2024 | |
| Ardelyx, INC. | $46.08 | 2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $41.64 | 2025 | Lupkynis |
| Veloxis Pharmaceuticals, INC. | $37.85 | 2024 | Envarsus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $29.52 | 2024-2025 | Rayaldee |
| Novo Nordisk INC | $27.98 | 2025 | Ozempic |
| Scpharmaceuticals INC. | $14.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.